Oncology is undergoing a significant digital transformation. As cancer treatments become more complex and data-driven, clinicians increasingly rely on specialized software to manage chemotherapy protocols, coordinate multidisciplinary care, and strive for treatment accuracy. What were once supporting tools—electronic records, protocol databases, and clinical calculators—have become core components of modern oncology practice. Within this shift, companies that focus specifically on oncology workflows are playing an ever-more significant role. Altai Oncology is one such company, contributing to the standardization and digitization of cancer care across diverse healthcare settings.
Altai Oncology, headquartered in Sheridan, Wyoming, develops medical software exclusively for hematology and oncology practices. Founded in 2013 by Ulas Darda Bayraktar, the company focuses on building digital systems that support chemotherapy management, clinical documentation, and protocol-based care. Its product portfolio includes the Altai Oncology Suite, the Altai Oncology Mobile App, and a comprehensive oncology protocol library, all designed to address the operational and clinical needs of cancer centers, infusion clinics, and individual oncology practices.
The Altai Oncology Suite serves as the company’s core platform. Implemented as a Windows-based system, it integrates chemotherapy order entry, automated dose calculations, scheduling, pharmacy workflows, cancer registry functions, reporting, and billing into a single environment. By consolidating these functions, the software enables oncology teams to manage complex treatment workflows more efficiently and with greater consistency. Clinicians can plan therapies using protocol-driven structures, minimize reliance on manual calculations, and align treatment decisions with documented clinical pathways.
Complementing the desktop platform, the Altai Oncology Mobile App extends access to key clinical resources beyond the workstation. Through the mobile application, clinicians can review oncology and hematology protocols, perform dose calculations, access staging modules, and consult reference materials from their mobile devices. The app is updated regularly to reflect evolving treatment standards and is designed to function as an integrated extension of the core system, supporting continuity across clinical environments.
A central component of Altai’s ecosystem is its Protocol Library, first established in 2015 and now comprising more than 1,000 chemotherapy and hematology treatment protocols. Developed and reviewed by oncology specialists, the library reflects current medical literature, clinical guidelines, and newly approved therapies. Integration of the protocol library into both desktop and mobile platforms ensures that clinical workflows are consistently aligned with the most up-to-date treatment standards, reducing the risk of manual errors and supporting evidence-based care.
Interoperability is another defining feature of Altai’s software architecture. The company’s systems are designed to connect with hospital information systems, laboratory platforms, and electronic health records using established communication standards such as HL7. This integration allows patient data, laboratory results, and treatment information to flow between systems without redundant data entry, potentially improving accuracy and operational efficiency.
Patient safety remains a central focus of the platform’s design. Built-in safeguards support dose calculations based on patient-specific parameters, laboratory values, and protocol-defined limits. Drug interaction alerts and structured verification steps further support error reduction during chemotherapy planning and administration. These features reflect the growing reliance on digital validation mechanisms in oncology, where treatment precision is critical.
Altai Oncology’s development approach is supported by a strong regulatory and quality framework. The company’s Turkish research and development arm, Altay Tıp Sağlık Yazılım AŞ, operates as the primary R&D center and is certified under ISO 13485, the international quality management standard for medical device software. In addition, the Altai Oncology Suite is CE-marked as a Class IIb medical device under European Medical Device Regulations, placing it within a regulated category of clinical software subject to defined safety and performance requirements.
Looking ahead, Altai Oncology continues to expand its software capabilities in response to evolving clinical and operational needs. The company has indicated plans to enhance system interoperability, extend integration with electronic health records, and develop additional modules tailored to specific oncology subspecialties. These efforts align with broader trends in oncology toward more coordinated care, structured data capture, and increasingly personalized treatment approaches.
Altai operates through a transcontinental model that combines U.S.-based corporate leadership with research and software development in Turkey. This structure has enabled the company to scale its platforms internationally while maintaining regulatory alignment and development continuity. Its users include hospitals, infusion centers, hematology departments, and independent oncology practitioners seeking structured digital tools for chemotherapy management and clinical documentation.
Through ongoing collaboration with healthcare professionals and institutions, Altai Oncology continues to refine its platforms based on real-world clinical use. Feedback from practitioners and data generated through clinical workflows inform product updates and protocol expansions. Beyond routine care, the software is also used in research environments, where standardized data collection and outcome tracking support clinical studies and quality improvement initiatives.
As oncology care increasingly depends on digital infrastructure, companies focused on specialty-specific solutions are becoming integral to healthcare delivery. Altai Oncology’s approach—centered on protocol standardization, workflow integration, regulatory compliance, and mobile accessibility—illustrates how oncology software is evolving from a supporting function into a foundational element of modern cancer care. In this context, Altai represents a growing segment of health technology companies shaping how oncology services are delivered, documented, and studied worldwide.
